MPL and autoimmune thrombocytopenic purpura: In 2008, the FDA approved the thrombopoietin receptor (TPO-R) agonist compound 15 (Eltrombopag, METTL3 IC50 = 3.65 μM) (Fig. 7C) for the treatment of chronic immune thrombocytopenia (ITP).